PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis

被引：9

作者：

Rossi, Antonio ^{[1
]}

Di Noia, Vincenzo ^{[2
]}

Gkountakos, Anastasios ^{[3
]}

D'Argento, Ettore ^{[4
]}

Sartori, Giulia ^{[5
]}

Vita, Emanuele ^{[2
]}

Monteverdi, Sara ^{[5
]}

Lombardo, Fiorella ^{[5
]}

Iacovelli, Roberto ^{[4
]}

Carbognin, Luisa ^{[5
,6
]}

Sperduti, Isabella ^{[7
]}

Milella, Michele ^{[5
]}

Tortora, Giampaolo ^{[2
]}

Bria, Emilio ^{[2
]}

Pilotto, Sara ^{[5
]}

机构：

[1] Sci Inst Res & Hlth Care IRCCS Casa Sollievo Soff, Dept Oncohematol, Div Med Oncol, San Giovanni Rotondo, FG, Italy

[2] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCC, Med Oncol, Comprehens Canc Ctr, Rome, Italy

[3] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Verona, Italy

[4] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Comprehens Canc Ctr, Rome, Italy

[5] Univ & Hosp Trust Verona, Azienda Osped Univ Integrata, Med Oncol, Dept Med, Verona, Italy

[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Div Gynecol Oncol, Dept Woman & Child Hlth, Rome, Italy

[7] IRCCS Regina Elena Natl Canc Inst, Biostat, Rome, Italy

来源：

IMMUNOTHERAPY | 2019年 / 11卷 / 10期

关键词：

atezolizumab; first line; immunotherapy; meta-analysis; nivolumab; NSCLC; PD-1; PD-L1; pembrolizumab;

D O I：

10.2217/imt-2018-0198

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p=0.001) and PFS (HR 0.61; p<0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.

引用

页码：921 / 930

页数：10

共 22 条

[1] [Anonymous], ANN ONCOL S8
[2] BORGHAEI H, 2018, J CLIN ONCOL S, V36
[3] Cappuzzo F, 2018, ANN ONCOL, V29
[4] Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Carbognin, Luisa
Pilotto, Sara
Milella, Michele
Vaccaro, Vanja
Brunelli, Matteo
Calio, Anna
Cuppone, Federica
Sperduti, Isabella
Giannarelli, Diana
Chilosi, Marco
Bronte, Vincenzo
Scarpa, Aldo
Bria, Emilio
Tortora, Giampaolo
[J]. PLOS ONE, 2015, 10 (06):
[5] European Medicines Agency, FIND MED KEYTR
[6] European Medicines Agency, FIND MED OPD
[7] European Medicines Agency, FIND MED TEC
[8] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Gandhi, L.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
De Angelis, F.
Domine, M.
Clingan, P.
Hochmair, M. J.
Powell, S. F.
Cheng, S. Y. -S.
Bischoff, H. G.
Peled, N.
Grossi, F.
Jennens, R. R.
Reck, M.
Hui, R.
Garon, E. B.
Boyer, M.
Rubio-Viqueira, B.
Novello, S.
Kurata, T.
Gray, J. E.
Vida, J.
Wei, Z.
Yang, J.
Raftopoulos, H.
Pietanza, M. C.
Garassino, M. C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
[9] Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Hanna, Nasser
Johnson, David
Temin, Sarah
Baker, Sherman, Jr.
Brahmer, Julie
Ellis, Peter M.
Giaccone, Giuseppe
Hesketh, Paul J.
Jaiyesimi, Ishmael
Leighl, Natasha B.
Riely, Gregory J.
Schiller, Joan H.
Schneider, Bryan J.
Smith, Thomas J.
Tashbar, Joan
Biermann, William A.
Masters, Gregory
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) : 3484 - +
[10] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Hellmann, M. D.
Ciuleanu, T. -E.
Pluzanski, A.
Lee, J. S.
Otterson, G. A.
Audigier-Valette, C.
Minenza, E.
Linardou, H.
Burgers, S.
Salman, P.
Borghaei, H.
Ramalingam, S. S.
Brahmer, J.
Reck, M.
O'Byrne, K. J.
Geese, W. J.
Green, G.
Chang, H.
Szustakowski, J.
Bhagavatheeswaran, P.
Healey, D.
Fu, Y.
Nathan, F.
Paz-Ares, L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2093 - 2104

← 1 2 3 →